U.S. markets close in 1 hour 14 minutes
  • S&P 500

    -58.31 (-1.45%)
  • Dow 30

    -450.78 (-1.31%)
  • Nasdaq

    -165.96 (-1.48%)
  • Russell 2000

    -34.84 (-1.86%)
  • Crude Oil

    +0.92 (+1.21%)
  • Gold

    -14.80 (-0.84%)
  • Silver

    -0.55 (-2.57%)

    -0.0052 (-0.50%)
  • 10-Yr Bond

    +0.0110 (+0.30%)

    -0.0126 (-1.05%)

    -0.2060 (-0.15%)

    -340.67 (-2.06%)
  • CMC Crypto 200

    -0.29 (-0.08%)
  • FTSE 100

    -12.65 (-0.17%)
  • Nikkei 225

    -120.20 (-0.42%)

PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020

PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its second quarter 2020 financial results and operational highlights before the Nasdaq market opens on Wednesday, August 19, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:


Wednesday, August 19, 2020


8:30 AM Eastern Time

United States:

+1 (877) 870-9135


+972 35308845


+44 (0) 2071 928338

Conference ID:




About PolyPid
PolyPid is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. PolyPid’s product candidates are designed to address diseases with high unmet medical needs by pairing PLEX with drugs to deliver them directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. PolyPid’s lead product candidate, D-PLEX100, is in Phase 3 clinical trials for the prevention of cardiac and abdominal surgical site infections. PolyPid’s technology and products are based on the inventions of Dr. Noam Emanuel, the Founder and the Chief Scientific Officer of the company.

For additional company information, visit www.polypid.com.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on PolyPid’s current expectations, they are subject to various risks and uncertainties. Actual results, performance or achievements of PolyPid could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in PolyPid’s final prospectus dated June 25, 2020, filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, PolyPid undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

CONTACT: Contacts: Company: PolyPid, Ltd. Dikla Czaczkes Akselbrad EVP & CFO Tel: +972-747195700 Investors: Bob Yedid LifeSci Advisors 646-597-6989 Bob@LifeSciAdvisors.com